Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes
Human autologous peripheral blood lymphocytes (PBLs) transduced with a glycoprotein 100 (gp100) epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector encoding the TCR specific for amino acid residues 154-162 of gp100 (KTWGQYWQV). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient and bind to melanoma cells expressing the gp100 protein, which may result in specific cytotoxic T-lymphocyte (CTL) killing of gp100-expressing melanoma cells. gp100 is a melanocyte lineage-specific antigen overexpressed in melanomas. [ ]
Term info
Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes
- Anti-p53 TCR-Transduced PBL
- Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes
- Autologous Anti-gp100:154-162 TCR Gene-Engineered PBL
NCIT_C128784
Autologous_Anti-gp100_154-162_TCR_Gene-engineered_PBL
CL376139
560190
560190
Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes
Pharmacologic Substance, Cell
C71748
Term relations
- T-cell Receptor-engineered T-cells
- Antineoplastic Immune Cell
- Therapeutic Autologous Lymphocytes
- Chemical_Or_Drug_Has_Physiologic_Effect some T-Cell Activation
- Chemical_Or_Drug_Affects_Cell_Type_Or_Tissue some Cytotoxic T-Lymphocyte
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Antigen Sensitization
- Chemical_Or_Drug_Has_Physiologic_Effect some Immunopotentiation